TABLE 3.
In vivo activity of ABT-255 against M. tuberculosis ATCC 35801 (strain Erdman)a in CF-1 mice
| Drug and doseb (mg/kg day−1) or group | Mean log10 no. of CFU/lung ± SE | Mean log10 reductionc |
|---|---|---|
| ABT-255 | ||
| 25 | 1.43 ± 0.49 | 5.46 |
| 12.5 | 3.58 ± 0.64 | 3.31 |
| 6.25 | 5.55 ± 1.34 | 1.34 |
| 3.13 | 7.00 ± 0.23 | 0 |
| Isoniazid | ||
| 25 | 1.69 ± 0.57 | 5.20 |
| 12.5 | 2.00 ± 0.56 | 4.89 |
| 6.25 | 1.96 ± 0.44 | 4.93 |
| 3.13 | 2.37 ± 0.59 | 4.52 |
| Infected controls | 6.89 ± 0.23 |
a
Inoculum of log10 7.00 mycobacteria.
b
Mice were dosed orally daily, from days 7 to 34 postinfection.
c
Difference in the mean log number of CFU from that of the day 35 late control group.